We are addressing the suffering
of insulin-dependent diabetics,
and leading to a proactive approach toward treatments.
Disease-Modifying Therapy
Our candidate drug is aimed at treating
Autoimmune Diabetes in the early stages
(Stage 2 of Type 1 Diabetes).
Currently, our pre-clinical study shows a unique safety advantage over other approved/investigational drugs and biologics targeting the immune system.
disables autoreactivity, deviates inflammatory processes, and possibly preserves beta cell survival.
Patented
Novel Ingredient
Orally
Administered
Long Term
Safety Profile
Founders
Daniella Givon
CEO
Clinical Herbalist. Head of the Integrative Herbal Medicine Dept., School of Complementary Medicine, G.W. College, Israel. 10 years' experience in herbal supplement development and regulatory affairs.
Nadav Shraibom
Director
MSc Traditional Chinese Medicine. Private practice clinician using TCM specializing in cancer, infertility, and auto-immune diseases.
Professor and Clinic Supervisor,
Pacific Ins. of Oriental Medicine, NY;
Founder/CEO Sirbal Ltd.
Raanan Margalit
head of Preclinical studies
Owner and CEO at "Science in Action" a boutique preclinical contract research organization founded in 2010 with extensive experience in tailor-made preclinical research in rodent models and in-vitro models.
Advisory
Prof. Mariana Rachmiel
Medical Advisor
Medical advisor, Professor Rachmiel is the Head of the Pediatric Endocrinology and Diabetes Institute at Shamir (Assaf Haroffeh) Medical Center, an Associate Professorat Sackler School of Medicine,Tel-Aviv University. She has completed Sackler School of Medicine in 1995, Magna Cum Lauda, She has completed Pediatric residency with at Shamir (Assaf Harofeh )Medical Center with excellency in 2004, and Pediatric Endocrinology fellow-ship at The Hospital for Sick Children Toronto, affiliated with Toronto University At 2006. She has been an active researcher with nearly 80 publications in peer-reviewed journals. She has been a reviewer at several journals, including Journal of Pediatrics, Acta Diabetologica, Pediatric Diabetes and JCEM during the last decade. She is a member of the ISPAD and ESPE international societies and Israeli HIPAK and PEIS . She is a member of the ESPE Summer School Committee.
Yaniv Aronowich
Legal advisor, Chief Legal Officer at accessiBe, a leader in web accessibility solutions. Previously, served as a tech and M&A partner at Tadmor & Co. Yuval Levy & Co., one of Israel's fastest growing independent law firms. Graduated law school at HUJI and pulic law affairs in TAU.
Dr. Avi Raveh
Principal investigator
Head of head of pharmaceutical R&D A natural product and a medicinal chemist. He joined the Blavatnik center for Drug Discovery as the head of the Medicinal Chemistry Unit and then became the Chief Scientific officer. Since 2018 he has been on the editorial board of Drug Development Research (Wiley). As of today, he is the Director of Chemistry, Materials, Nanotechnology, and Energy Director of Chemistry, Materials, Nanotechnology, and Energy Israel's Ministry of Innovation.
Urs Wiedemann
Pharmaceutical Biz-Dev
Biz-Dev advisor, Founder and Managing Partner of stradoo, a life sciences focused strategy consulting firm. During the past 15 years, Urs has advised numerous pharmaceutical companies – from biotech startups to big pharma – on R&D and therapeutic area strategy, portfolio management, market entry strategy and commercialization models. Before turning to strategy consulting, he worked within life sciences both in academia and the industry, following his Master in Molecular Biology and PhD in Biochemistry and Structural Biology.
Type 1 Diabetes affects millions of people,
children and adults globally, adding more than 3K patients to the insulin dependency cycle every year
Every day hundreds of children and adults are newly diagnosed with Type 1 Diabetes
and sentenced to a lifetime burden & health risk. There is a continuously growing number of Type 1 Diabetes patients & needs
Type 1 Diabetes patients are lifelong dependent on insulin –
it is their lifeline even though it does not address the underlying disease cause.
No other preventive or disease-modifying therapy
is currently available to address the underlying case of Type 1 Diabetes.
Risk group
It has been proven that first-degree relatives (siblings or children) of Type 1 diabetes patients are at greater risk of developing the disease.
As a result, 22m people will contract Diabetes by 2040,
and face the daily burden of living with Type 1 Diabetes.
Total Type 1 Diabetes treatment market in US, CAN, EU5, JPN covering drug therapies
(incl. insulin, GLP-1, and SGLT-2 inhibitors).
Of about 374,000 plant species that humanity is currently aware of,
only 6% have been investigated pharmacologically*
For decades humanity had relied on naturally sourced ingredients for medicinal purposes.
The Green Revolution also is known as the Third Agricultural Revolution,
brought many changes to human health; Processed food, petrochemicals in the form of herbicides and pesticides, hormones, and other endocrine disruptors,
are new factors in our nutrition and have a massive effect on our health.
Another major and significant change is the constantly
decreasing consumption of naturally sourced molecules and compounds.
Looking through the pharmaceutical industry forecast**, new modalities, such as cell and gene therapy and mRNA vaccine technology, might offer fragmentation of technology, new supply chains, and unique product life cycles.
However, we cannot say they offer better and safer patient health
as they often include immunosuppressant support.
Only time will tell.
Our R&D team, each in their field of professionality, promotes safe and effective therapies and technologies that prompt sustainable health and manufacturing process.
Together, we took the challenge of developing a safe and effective
Disease-Modifying Therapy which will be a game changer
for Diabetic societies around the world.
*Evaluating natural medicinal resources and their exposure to global change, Theodoridis, Drakou, Hickler, Thines, Nogues-Bravo, 2023
**Emerging from disruption: The future of pharma operations strategy, By Hillary Dukart, Laurie Lanoue, Mariel Rezende, and Paul Rutten, MecKinsry 2022
Our story
A few years ago, Daniella had to face a new reality with her oldest daughter who was diagnosed with Type 1 Diabetes. The whole family had to adjust to a typical Type 1 routine that includes daily injections, blood tests (up to 6 times a day!), a strict diet and a general existence of frustration.
Getting familiar with this disease, Daniella realized that her daughter was walking around for months as this chronic disease was slowly developing inside her.
She couldn't help thinking: What if it's only a matter of taking action at the right time and we could actually prevent the progress of this chronic disease?
Apparently, there are hundred thousands of children and adults in this pre-diabetic stage who are walking around like time bombs not knowing what a poor destiny awaits them. And why? Because they are not diagnosed in time and not receiving timely or correct treatment.
Thinking that her other daughter, as a first-degree relative, is one of the only known risk groups that can easily be tracked and treated before it's too late, Daniella decided to take action and gathered a professional team that works to change the mindset about chronic disease therapy and gives treatment as early as possible in order to prevent it.
We want to hear from you!
Our mission of preventing Type 1 diabetes is a complex one.
All stakeholders who can assist us or be assisted by us are invited to drop us a line.